Assessing health-related quality of life in patients with benign non-toxic goitre

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Standard

Assessing health-related quality of life in patients with benign non-toxic goitre. / Watt, Torquil; Cramon, Per; Frendl, Daniel M.; Ware, John E.

I: Best Practice and Research: Clinical Endocrinology and Metabolism, Bind 28, Nr. 4, 08.2014, s. 559-575.

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Harvard

Watt, T, Cramon, P, Frendl, DM & Ware, JE 2014, 'Assessing health-related quality of life in patients with benign non-toxic goitre', Best Practice and Research: Clinical Endocrinology and Metabolism, bind 28, nr. 4, s. 559-575. https://doi.org/10.1016/j.beem.2014.01.009

APA

Watt, T., Cramon, P., Frendl, D. M., & Ware, J. E. (2014). Assessing health-related quality of life in patients with benign non-toxic goitre. Best Practice and Research: Clinical Endocrinology and Metabolism, 28(4), 559-575. https://doi.org/10.1016/j.beem.2014.01.009

Vancouver

Watt T, Cramon P, Frendl DM, Ware JE. Assessing health-related quality of life in patients with benign non-toxic goitre. Best Practice and Research: Clinical Endocrinology and Metabolism. 2014 aug.;28(4):559-575. https://doi.org/10.1016/j.beem.2014.01.009

Author

Watt, Torquil ; Cramon, Per ; Frendl, Daniel M. ; Ware, John E. / Assessing health-related quality of life in patients with benign non-toxic goitre. I: Best Practice and Research: Clinical Endocrinology and Metabolism. 2014 ; Bind 28, Nr. 4. s. 559-575.

Bibtex

@article{ff4a1a4e23d84182a996d1670d008f28,
title = "Assessing health-related quality of life in patients with benign non-toxic goitre",
abstract = "Health-related quality of life (HRQoL) assessments are increasingly used to evaluate treatment effects and to shape the delivery of value based care. Valid generic and disease specific tools are available for quantifying HRQoL in patients with non-toxic goitre. However, few studies have applied these validated instruments to assess HRQoL in patients with benign non-toxic goitre. Limited evidence suggests that patients with non-toxic goitre have HRQoL impairments in multiple HRQoL domains. While the HRQoL-impact of non-toxic goitre may be small relative to other severely disabling medical conditions, treatment is almost exclusively elected for HRQoL indications. Thus better quantification of HRQoL, particularly at better (or more favorable) levels where many patients score, is essential. Web and mobile technologies have eased the ability to deliver surveys to patients. Routine consideration of HRQoL provides the opportunity to monitor the impact of treatment on the outcomes most meaningful for patients and the opportunity to help shape the delivery of value based health care.",
keywords = "non-toxic goitre, patient-reported outcome measure, quality of life",
author = "Torquil Watt and Per Cramon and Frendl, {Daniel M.} and Ware, {John E.}",
note = "Funding Information: We would like to thank Mikel Strom, MSLIS, for helping to design and perform the literature search for this systematic review. This work was supported by the Danish Agency for Science, Technology and Innovation (grant 271-09-0143 ) and the Danish Council for Independent Research (grant 09-066886 ). L.H. is supported by an unrestricted research grant from the Novo Nordisk Foundation , and U.F.-R. from Arvid Nilsson's Fund . S.J.B. is supported by an unrestricted research grant from The Research Council at Odense University Hospital .",
year = "2014",
month = aug,
doi = "10.1016/j.beem.2014.01.009",
language = "English",
volume = "28",
pages = "559--575",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Assessing health-related quality of life in patients with benign non-toxic goitre

AU - Watt, Torquil

AU - Cramon, Per

AU - Frendl, Daniel M.

AU - Ware, John E.

N1 - Funding Information: We would like to thank Mikel Strom, MSLIS, for helping to design and perform the literature search for this systematic review. This work was supported by the Danish Agency for Science, Technology and Innovation (grant 271-09-0143 ) and the Danish Council for Independent Research (grant 09-066886 ). L.H. is supported by an unrestricted research grant from the Novo Nordisk Foundation , and U.F.-R. from Arvid Nilsson's Fund . S.J.B. is supported by an unrestricted research grant from The Research Council at Odense University Hospital .

PY - 2014/8

Y1 - 2014/8

N2 - Health-related quality of life (HRQoL) assessments are increasingly used to evaluate treatment effects and to shape the delivery of value based care. Valid generic and disease specific tools are available for quantifying HRQoL in patients with non-toxic goitre. However, few studies have applied these validated instruments to assess HRQoL in patients with benign non-toxic goitre. Limited evidence suggests that patients with non-toxic goitre have HRQoL impairments in multiple HRQoL domains. While the HRQoL-impact of non-toxic goitre may be small relative to other severely disabling medical conditions, treatment is almost exclusively elected for HRQoL indications. Thus better quantification of HRQoL, particularly at better (or more favorable) levels where many patients score, is essential. Web and mobile technologies have eased the ability to deliver surveys to patients. Routine consideration of HRQoL provides the opportunity to monitor the impact of treatment on the outcomes most meaningful for patients and the opportunity to help shape the delivery of value based health care.

AB - Health-related quality of life (HRQoL) assessments are increasingly used to evaluate treatment effects and to shape the delivery of value based care. Valid generic and disease specific tools are available for quantifying HRQoL in patients with non-toxic goitre. However, few studies have applied these validated instruments to assess HRQoL in patients with benign non-toxic goitre. Limited evidence suggests that patients with non-toxic goitre have HRQoL impairments in multiple HRQoL domains. While the HRQoL-impact of non-toxic goitre may be small relative to other severely disabling medical conditions, treatment is almost exclusively elected for HRQoL indications. Thus better quantification of HRQoL, particularly at better (or more favorable) levels where many patients score, is essential. Web and mobile technologies have eased the ability to deliver surveys to patients. Routine consideration of HRQoL provides the opportunity to monitor the impact of treatment on the outcomes most meaningful for patients and the opportunity to help shape the delivery of value based health care.

KW - non-toxic goitre

KW - patient-reported outcome measure

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84904722182&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2014.01.009

DO - 10.1016/j.beem.2014.01.009

M3 - Review

C2 - 25047206

AN - SCOPUS:84904722182

VL - 28

SP - 559

EP - 575

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 4

ER -

ID: 303679272